Chronic Rinosinusitis & Polyposis

There’s a science to the art of breathing free. And it begins with research. The ECLIPSE study is researching treatment for adults with chronic rhinosinusitis with nasal polyposis.

Why is this study important?

If you have chronic rhinosinusitis with nasal polyposis (CRSwNP), you probably know that nasal polyps can cause congestion, runny nose, pain or pressure in your face and/or a reduced sense of smell. You may have used other treatments or had surgery to try to control these uncomfortable symptoms. However, nasal polyps usually come back—even after other treatments or surgery. Some people with nasal polyps may need longer lasting control.

What is the purpose of this study?

The purpose of this clinical trial is to test the safety and effectiveness of the study drug, etokimab. The study drug (etokimab or placebo) will be given by subcutaneous injection every 4 weeks for 4 months. A placebo looks like the test medicine but contains no active ingredients (medicine). Subcutaneous injections are given just under the skin into a layer of body fat (the tummy or upper arms).

Who can participate?

To be eligible for this study, you must:

  • Be 18 to 70 years of age
  • Have nasal polyps in both nostrils
  • Have at least 2 of the following symptoms:
    • Nasal blockade/obstruction
    • Nasal congestion
    • Nasal discharge (anterior/posterior nasal drip)
    • Facial pain/pressure
    • Reduction or loss of smell
  • Be a non-smoker
  • Sign the informed consent form

This is not a complete list of eligibility criteria. The study doctor will review the full criteria for this study with you.

What does participating involve?

Your participation in this study will last approximately 28 weeks (7 months start to

finish) and you will come to the study center for about 9 visits. There is a possibility you may need to return for additional visits if your study doctor believes it is necessary.

There are 3 dosing groups receiving different doses of study drug. You will be assigned randomly (like the flip of a coin) to one of the 3 dosing groups. You have a greater than 50% chance of being in one for the active treatment groups.

This is a blinded study, which means neither you nor the study doctor will know to which of these study groups you are assigned. In case of an emergency; however, the study doctor can get this information.

Lab tests, a physical exam, and other assessments will be conducted at the in-clinic visits. Not all activities will occur at every visit.

 What are the benefits?

You may benefit as a result of your participation in this study. There is, however, no guarantee that you will benefit from your participation in this study. Information learned from the study may help other people in the future.

There will be no charge to you for your participation in this study. The study drug, study-related procedures, and study visits will be provided at no charge. You will be reimbursed for reasonable and acceptable study-related travel costs.

What are the risks?

Any study has risks, which may include things that could make you feel uncomfortable, ill, or in rare situations harm you. You might experience side effects related to the study drug while participating in the study. All participants in the study will be watched carefully for any side effects; however, the study team does not know all the effects that the study product(s) may have on you.

The study team may give you medicines to help reduce side effects. These side effects may be

mild or serious. In some cases, these side effects might be long-lasting, or permanent, and may

even be life-threatening. In previous studies, the study drug was generally safe and well-tolerated. Some mild to moderate symptoms were experienced by participants, such as:

  • upper respiratory tract infection (common cold)
  • headache
  • abdominal pain
  • nausea
  • vomiting
  • rash
  • tiredness

A condition called cytokine release syndrome may also occur, with symptoms such as:

  • Mild to moderate fever, chills, headache, nausea, and vomiting
  • Moderate to severe symptoms such as swelling of the skin, low blood pressure and blood and mucus in the lungs

What should I do now?

If participating in this research study is something you think you might be interested in, please talk with your family and then to your doctor. If you wish to take the next step toward possible participation, or have more questions, please fill out the form on this page and we will contact you shortly. Contacting us does not obligate you to participate in this research study.